EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as ...

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

BMO Capital opined on Monday that recent reports indicating Robert F. Kennedy Jr.'s plan to remove all members of the U.S.

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...